Drugs targeting KHK are currently in the pipeline, including the small molecule inhibitor PF‐06835919260 and the GalNAc‐siRNA drug ALN‐KHK (Table 5), which have demonstrated good efficacy (i.e., prevention of fructose‐induced hyperlipidemia, hyperinsulinemia, and steatosis).261. The gene discussed is KHK; the disease is steatosis.